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Neurodegenerative diseases are devastating medical conditions with no effective
treatments. Restoration of impaired neurogenesis represents a promising therapeutic
strategy for neurodegenerative diseases. Milk fat globule-epidermal growth factor-factor
VIII (MFG-E8) is a secretory glycoprotein that plays a wide range of cellular functions
including phagocytosis of apoptotic cells, anti-inflammation, tissue regeneration, and
homeostasis. The beneficial role of MFG-E8 has been shown in cerebral ischemia
(stroke), neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s
disease, and traumatic brain injury. In stroke, MFG-E8 promotes neural stem cell
proliferation and their migration toward the ischemic brain tissues. These novel
functions of MFG-E8 are primarily mediated through its receptor αv β3 -integrin. Here,
we focus on the pivotal role of MFG-E8 in protecting against neuronal diseases by
promoting neurogenesis. We also discuss the mechanisms of MFG-E8-mediated neural
stem/progenitor cell (NSPC) proliferation and migration, and the potential of MFG-E8 for
neural stem cell niche maintenance via angiogenesis. We propose further investigation
of the molecular pathways for MFG-E8 signaling in NSPC and effective strategies for
MFG-E8 delivery across the blood–brain barrier, which will help develop MFG-E8 as a
future drug candidate for the bedside management of neurodegenerative diseases.
Keywords: neurogenesis, neurodegenerative diseases, MFG-E8, Alzheimer’s disease, Parkinson’s disease, stem
cells, integrin, apoptosis
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Neurodegenerative diseases are a heterogeneous group of brain disorders of multifactorial
etiologies characterized by the loss of existing neurons and alterations in neuronal replacement
via neurogenesis (De Pablo-Fernández et al., 2019; Zetterberg and Schott, 2019). Common
neurodegenerative diseases with alterations in neurogenesis include Parkinson’s disease,
Alzheimer’s disease (AD), Huntington disease, Schizophrenia, and Prion disease (Winner and
Winkler, 2015; Horgusluoglu et al., 2017; De Pablo-Fernández et al., 2019; Zetterberg and
Schott, 2019). These diseases have different clinical manifestations due to different pathological
mechanisms occurring in different parts of the brain. However, the ultimate result of the
different disease mechanisms at the cellular level is loss of neurons and other cells in the brain.
Therefore, pharmacological modulation of the process of neuronal renewal via neurogenesis and
inhibition of neuropathological processes is a promising therapeutic strategy (Cheyuo et al., 2015;
Hachem et al., 2017).
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Huttner, 2005; Tsunekawa and Osumi, 2012). RGL support the
migration of neuroblasts to the outer layers of the developing
cortex where they differentiate into neurons (Götz and Huttner,
2005). The dynamic clonal lineage progression from NSPC to
neurons may involve at least four different cell states, namely –
quiescent cells, active proliferating cells, transient amplifying
progenitors (TAP) and neuroblasts, which ultimately differentiate
into neurons after migration (Bast et al., 2018). Neurogenesis is
initiated in the neural stem cell niche from the quiescent cells,
which upon activation go into a proliferative phase, followed
by migration of neuroblasts and eventually differentiation into
neurons (Alvarez-Buylla and Garcia-Verdugo, 2002). In the adult
brain, neurogenesis is maintained in the subventricular zone and
dentate gyrus, which contain neural stem cell niches (GarcíaVerdugo et al., 1998; Doetsch et al., 1999; Bast et al., 2018).
The process of neurogenesis holds therapeutic potential for brain
diseases characterized by neuronal cell loss.

Milk fat globule-epidermal growth factor-factor VIII (MFGE8) is a secreted glycoprotein which has two epidermal growth
factor (EGF)-like domains from the mouse or one EGF-like
domain from human at the N-terminal site, and two discoidin
domains at the carboxy terminal site from both (Aziz et al., 2011).
Depending on the species and post-translational modifications
the molecular weight of MFG-E8 varies from 46 to 75 kD (Aziz
et al., 2011). The EGF-like domain has an RGD (Arg-Gly-Asp)
motif which recognizes integrins αv β3 and αv β5 mainly expressed
on macrophages (Hanayama et al., 2002, 2004; Aziz et al., 2011).
The discoidin domain of MFG-E8 recognizes phosphatidylserine
(PS) exposed on the cell membranes of apoptotic cells (Hanayama
et al., 2002, 2004; Aziz et al., 2011). This unique structure of MFGE8 enables it to mitigate several pathological processes involved
in neurodegenerative diseases.
MFG-E8-mediated phagocytic clearance of apoptotic cells by
the macrophages (Hanayama et al., 2002; Fuller and Van Eldik,
2008; Aziz et al., 2011) is one of the mechanisms by which
hyperinflammation in brain diseases can be inhibited. MFGE8-mediated phagocytosis of prion infected apoptotic cells also
helps control prion disease in mice (Kranich et al., 2010). MFGE8 has been shown to bind amyloid-beta peptide (ABP) and
facilitate ABP clearance by the glial cells to protect mice against
the development of AD (Boddaert et al., 2007), even though in
a mouse model of Parkinson’s disease, MFG-E8 deficiency did
not impact of the clearance of apoptotic bodies (Kinugawa et al.,
2013). Although phagocytic clearance of apoptotic cells/debris is
useful in protecting against neurodegenerative diseases, in the
current review we will primarily focus on the plausible role of
MFG-E8 on neurogenesis in neurodegenerative diseases.
MFG-E8 has been shown to promote cell proliferation and
cell migration through its receptors αv β3 -integrin and PS (Bu
et al., 2007; Aziz et al., 2011; Wang et al., 2012; Cheyuo et al.,
2015). Therefore, besides phagocytic clearance of apoptotic cells
or debris, proliferation and migration of stem cells as reported
in murine cerebral ischemia (Cheyuo et al., 2015), regeneration
of injured tissues, and mitigation of overall inflammation
as mediated by MFG-E8 provide strong scientific ground to
establish MFG-E8 as a promising candidate therapeutic agent for
neurodegenerative diseases.

MFG-E8 AND NEURODEGENERATIVE
DISEASES
Neurodegenerative diseases are irredeemable and devastating
clinical conditions that result in the degeneration and/or death of
neuronal cells (Winner and Winkler, 2015; Zetterberg and Schott,
2019). Examples of neurodegenerative diseases with alterations
in neurogenesis include Parkinson’s disease, Alzheimer’s disease,
Huntington disease, Schizophrenia and Prion disease (Winner
and Winkler, 2015; Horgusluoglu et al., 2017; De PabloFernández et al., 2019; Zetterberg and Schott, 2019). Parkinson’s
disease is characterized pathologically by intracellular deposits
of α-synuclein and degeneration of neurons (Schulz-Schaeffer,
2010). The disease process affects the hippocampus and olfactory
bulb early (Kohl et al., 2012). Decreased neurogenesis is observed
in both animal models of Parkinson’s disease and human postmortem studies (Höglinger et al., 2004; Kohl et al., 2012).
Alzheimer’s disease is a common type of dementia, characterized
pathologically by neurofibrillary tangles and amyloid plaques,
with widespread degenerative changes involving the basal
forebrain and limbic system (Hardy and Selkoe, 2002; Zetterberg
and Schott, 2019). Hippocampal neurogenesis has been shown
to be impaired in Alzheimer’s disease (Sun et al., 2009; Mu
and Gage, 2011; Zetterberg and Schott, 2019). In Huntington
disease, there is a trinucleotide expansion within the Huntington
gene due to an autosomal dominant mutation (Pringsheim et al.,
2012). The proliferation of neural stem cells is not affected in
Huntington disease but there is impaired maturation of neurons
in the striatum (Phillips et al., 2005; Winner and Winkler,
2015). Schizophrenia is another common neurodegenerative
disorder characterized clinically by delusions, hallucinations,
thought disorder, and movement disorder. Cognitive impairment
in schizophrenia is correlated with disruption of neurogenesis
(Reif et al., 2006; Lee et al., 2015). Prion disease, also
known as Creutzfeldt-Jakob disease in humans, is a fatal
neurodegenerative disease caused by host-encoded cellular prion
protein (PrPC) misfolding into infectious disease-provoking
multimeric aggregates, called prions (Kupfer et al., 2009). The

NEUROGENESIS
During early corticogenesis [embryonic day 9 (E9) to E11 in
mice], neural stem/progenitor cells (NSPCs) expand clonally
through symmetrical cell division, producing two similar selfrenewing daughter cells (Haubensak et al., 2004; Radakovits
et al., 2009; Tsunekawa and Osumi, 2012). From E11, NSPC
transform morphologically into thin, elongated, asymmetrically
dividing cells called radial glial cells (RGL; Noctor et al.,
2001; Götz and Huttner, 2005). Asymmetrical division produces
two daughter cells with different fates – an apical progenitor
(AP) with self-renewing capacity through further asymmetrical
divisions, and an intermediate progenitor (IP) which divides
symmetrically to produce two daughter cells that undergo
differentiation into neurons (Noctor et al., 2001; Götz and
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critical for corticogenesis through the regulation of neurogenesis
(Fietz et al., 2010). Mammalian integrins consist of 8 β-subunits
and 16 α-subunits, which can combine to generate 24 known
functional receptor types (Prowse et al., 2011). In NSPC, the
β1 -subunit is the most commonly expressed integrin subunit,
being expressed by 94% of human NSPC (Flanagan et al.,
2006). The MFG-E8 receptor, αv β3 integrin, is expressed in
human, ferret and mouse NSPCs (Fietz et al., 2010; Stenzel
et al., 2014). RGL, which divide asymmetrically, are elongated
NSPC with polarity maintained by differential expression of
molecules in their basal and apical processes. Fietz et al. (2010)
found that β3 -integrin was expressed in the basal processes
of asymmetrically dividing NSPC and that disruption of its
function resulted in decreased expansion. Similarly, Stenzel
et al. (2014) demonstrated that activation of αv β3 -integrin
promoted NSPC expansion in the mouse embryonic neocortex.
The crucial role of αv -integrin in mouse brain development
was characterized by McCarty et al. (2002) in αv -null mice.
These mice were found to develop intracerebral hemorrhage
mid-gestation and die shortly after birth. These knockout mice
displayed normal endothelium-pericyte associations and interendothelial cell junctions. However, the cause of hemorrhage
was revealed to be defective associations between cerebral microvessels and the surrounding brain parenchyma, composed of
neuroepithelial cells, glia, and neuronal precursors. In addition,
these mice also developed disorganized neuroepithelial processes
in their ganglionic eminences. Integrin β3 and β5 knockout mice
on the other hand, did not cause cerebral hemorrhages (McCarty
et al., 2002). Of note, β5 -integrin expression has not been
characterized in neural stem cells (Prowse et al., 2011). Using the
Cre/Lox system, McCarty et al. (2005) further characterized the
effect of conditional deletion of αv -integrin in central nervous
system glia and neurons. Mice with this conditional deletion of
αv -integrin also developed cerebral hemorrhage. Surviving mice
subsequently developed severe neurological deficits and seizures
and died by age 4 weeks (McCarty et al., 2005). On the other
hand, integrin β3 knockout in mice is not lethal (Carter et al.,
2011). Integrin β3 knockout mice have been found to display
altered social and repetitive behavior relevant to autism spectrum
disorders (Carter et al., 2011). In summary, the above studies
have demonstrated the pivotal role of the MFG-E8 receptor,
αv β3 integrin, in NSPC expansion and maintenance of the
associations between cerebral micro-vessels and the surrounding
brain parenchyma.

prions are capable of infecting neural stem cells and altering
neuronal destiny during neurogenesis (Relaño-Ginés et al., 2014).
Most of the current treatments of neurodegenerative diseases
only relieve symptoms or slow down disease progression, without
a true cure. Given the progressive nature of these diseases,
with continuing neuronal loss, there comes a time when the
treatments become ineffective or side effects become unbearable
with dose escalation. To counter the loss of neurons with disease
progression, induction of neurogenesis could be a promising
therapeutic strategy in neurodegenerative diseases (Cheyuo et al.,
2015; Hachem et al., 2017).
MFG-E8 is expressed by a wide variety of cells, including
immune cells, astrocytes, microglia and neural stem cells,
mesenchymal stem cells and hematopoietic stem cells (Aziz
et al., 2011; Cheyuo et al., 2012, 2015). MFG-E8 signaling in
these cells has been shown to promote apoptotic cell clearance,
suppress inflammation, and induce neurogenesis (Aziz et al.,
2011; Cheyuo et al., 2015). The anti-inflammatory and antiapoptotic roles of MFG-E8 have been described in various
animal models of brain injury (Cheyuo et al., 2012, 2015;
Gao et al., 2018). In rodent model of cerebral ischemia, it
has been shown that MFG-E8 inhibits inflammasome-induced
production of interleukin-1β (IL-1β) by macrophages (Deroide
et al., 2013). MFG-E8 promotes this anti-inflammatory effect
via the interaction of integrin β3 and P2 X7 receptors (Deroide
et al., 2013). In a separate study, MFG-E8 was also found
to significantly reduce the expression of the inflammatory
cytokine, IL-6, after cerebral ischemia (Cheyuo et al., 2012). In
addition, MFG-E8 also inhibits neuronal apoptosis by increasing
increased bcl-2/bax ratio (Cheyuo et al., 2012). Bok et al. (2017)
found that the MFG-E8 gene was a target of hypoxia-inducible
factor-1α (HIF-1α), which helps regulate microglial functions
affecting neuronal survival in ischemic stroke. In an animal
model of subarachnoid hemorrhage, MFG-E8 reduced neuronal
cell death via decreased expression of cleaved caspase-3 and
IL-1β (Liu et al., 2015). These studies highlight the potential to
ameliorate acute brain injury. Recent studies have also revealed
an emerging role of MFG-E8 in regenerative brain repair process
of neurogenesis (Cheyuo et al., 2015; Zhou et al., 2018), which
shed lights on the development of MFG-E8 as a novel enhancer
of neurogenesis in neurodegenerative diseases. By inhibiting the
deleterious processes of neuro-inflammation and apoptosis while
enhancing neuronal regeneration as described above, MFG-E8
has the potential to be developed as a therapeutic agent for
neurodegenerative diseases.

αv β3 -INTEGRIN-MEDIATED SIGNAL
TRANSDUCTION PATHWAY

EXPRESSION AND ROLE OF MFG-E8
RECEPTOR, αv β3 -INTEGRIN, IN NSPC

The signal transduction pathways through which the αv β3 integrin receptor mediates its myriad cellular effects are complex
and are covered in great detail elsewhere in the literature
(Desgrosellier et al., 2009; Schiller and Fässler, 2013; Xiao
et al., 2013). Briefly, engagement of the αv β3 -integrin with its
ligands causes clustering of the integrin in the membrane and
concentration of intracellular signaling molecules (Berrier and
Yamada, 2007). Clustering of the β3 -integrin intracellular domain

Crucial to the development of MFG-E8 as a modulator of
neurogenesis is the question of whether or not its receptor,
αv β3 integrin, is expressed in NSPC? Integrins are a family
of receptors, consisting of heterodimers of α- and β-subunits,
which control cellular processes by binding to extracellular
matrix (ECM), soluble extracellular ligands or cell surface
molecules (Berrier and Yamada, 2007). Integrin signaling is
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2005). Molecules distributed in the basal process include cyclin
D2 and integrins, which interact with ECM molecules in the
basal lamina. Apically distributed molecules include centrosomal
proteins, cell adhesion molecules and prominin 1 (Tsunekawa
and Osumi, 2012; Tsunekawa et al., 2014). The basally biased
location of cyclin D2, a cell cycle regulator, results in asymmetric
inheritance of cyclin D2 after asymmetric cell division, leading
to cell fate determination. In a model of cell fate determination
described by Tsunekawa et al. (2014), cyclin D2 mRNA is
transported to the basal endfoot during G1 , S- to G2 -phase
due to the cis-transport element that resides in the 30 UTR
region of cyclin D2 mRNA together with the transportation
machinery that recognizes the cis element. The transported
mRNA is locally translated into protein via ribosomes localized
at the basal endfoot (Tsunekawa et al., 2014). During mitosis,
cyclin D2 protein is inherited by one of the daughter cells
with its basal process. The daughter cell that has inherited
cyclin D2 with the basal process remains as a progenitor,
whereas the other daughter without the cyclin D2 proceeds to
differentiation (Tsunekawa and Osumi, 2012; Tsunekawa et al.,
2014). The behavior of NSPC in the niche are complex and
poorly understood. Bast et al. (2018) performed in vivo clonal
lineage analysis in double hemizygous GLASTCreERT2 :Confetti
transgenic mice and used a mathematical model to quantify
lineage transitions in young and aged mice. They found that
asymmetric division was the dominant mode of NSPC division
with aging and was the main driver of NSPC quiescence
(Bast et al., 2018).

activates non-receptor tyrosine kinases such as focal adhesion
kinase (FAK) and Src, resulting in increased concentrations of
tyrosine-phosphorylated proteins (Berrier and Yamada, 2007;
Desgrosellier et al., 2009). Different types of proteins with
different functions are recruited to the integrin receptor
activation complex. These proteins may include scaffolding
proteins, such as talin, which link integrins to cytoskeletal
components such as actin, α-actinin and vinculin, leading
to stimulation of cell migration (Berrier and Yamada, 2007).
Serine/threonine kinases, such as phosphoinositide 3 kinase
(PI3K), have also been shown to be recruited to integrin receptor
activation complex, where they interact with FAK and Src, leading
to the downstream regulation of the cell cycle via regulation
of cyclins and cyclin dependent kinases (Schwartz and Assoian,
2001). The specific aspects of the complex αv β3 -Integrinmediated signal transduction pathway activated by MFG-E8 are
discussed in the later part of the review.

NEURAL STEM CELL NICHE
Neurogenesis in the postnatal brain is restricted to the
subventricular zone and the dentate gyrus, which contain niches
where NSPC reside (Alvarez-Buylla and Garcia-Verdugo, 2002).
The neural stem cell niche is a specialized unit consisting of
capillaries in planar configuration, in direct contact with NSPC.
The unique neurovascular interface of the niche lacks the typical
endothelial tight-junctions, astrocyte endfeet and pericytes that
make up the typical blood–brain barrier (BBB; Tavazoie et al.,
2008). Indeed, tracer experiments demonstrated high tracer
uptake at the subventricular zone, confirming a leaky BBB at
the neural stem cell niche (Tavazoie et al., 2008). This suggests
that small molecules in the circulation may be able to cross
this barrier to modulate neurogenesis. The neural stem cell
component of the niche consists of NSPC in different stages of
the cell cycle (Bast et al., 2018). Quiescent neural stem cells are
cells in the G0 phase that retain the ability to re-enter the cell
cycle and contribute to cell proliferation (Daynac et al., 2013).
Proliferating cell populations in the neural stem cell niche include
active proliferating neural stem cells, TAP and proliferating
neuroblasts (Bast et al., 2018). Non-proliferating neuroblasts
are committed progenitors which migrate out of the niche to
other parts of the brain where they undergo differentiation
(Thored et al., 2007).
NSPC in the niche expand by two main types of cell
division – asymmetric and symmetric cell divisions (Bast
et al., 2018). Symmetric cell division produces two similar selfrenewing daughter cells. Asymmetric cell division on the other
hand produces two daughter cells with different fates – one
daughter cell is self-renewing while the other daughter cell
becomes committed to differentiation (Tsunekawa and Osumi,
2012). From E-11, NSPC transform morphologically into thin,
elongated, asymmetrically dividing cells called RGL. Each RGL
has a basal process and an apical process (Noctor et al., 2001;
Götz and Huttner, 2005). RGL are molecularly polarized, with
different patterns of protein expression profiles between the basal
and apical processes (Noctor et al., 2001; Götz and Huttner,
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MFG-E8-MEDIATED INDUCTION OF
NEUROGENESIS
MFG-E8 and its receptor, αv β3 -integrin, are expressed by
NSPC, thus suggesting a pivotal role of MFG-E8 in the
regulation of neurogenesis (Fietz et al., 2010; Stenzel et al.,
2014; Cheyuo et al., 2015; Zhou et al., 2018). A recent study
demonstrated the effects of MFG-E8 on neurogenesis, using a
rodent model of ischemic stroke (Cheyuo et al., 2015). Stroke
was induced in wild-type (WT) and MFG-E8-deficient (MFGE8−/− ) mice by transient middle cerebral artery occlusion
(tMCAO; Cheyuo et al., 2015). They found that treatment
of recombinant human MFG-E8 significantly improved the
neurological deficit score, body weight loss and neural stem
cell proliferation after tMCAO. Conversely, decreased neural
stem cell proliferation was observed in MFG-E8−/− mice in
comparison with the WT counterparts which underwent tMCAO
(Cheyuo et al., 2015). Recombinant murine MFG-E8 stimulated
the proliferation of mouse embryonic neural stem cells via
upregulation of cyclin D2 and downregulation of p53, through
αv β3 -integrin signaling (Cheyuo et al., 2015). Recombinant
murine MFG-E8 also promoted mouse embryonic neural stem
cell migration via αv β3 -integrin dependent upregulation of
netrin-1 (Cheyuo et al., 2015).
Cyclin D2 is the only D-type cyclin expressed in NSPC,
thus making it essential for NSPC biology (Kowalczyk et al.,
2004). Tsunekawa et al. have shown that cyclin D2 is a basal
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cell-fate determinant during asymmetrical cell division in NSPC
as described above (Tsunekawa and Osumi, 2012; Tsunekawa
et al., 2014). Cyclin D2 knockout mice have been shown to
have suppressed neurogenesis and pharmacological suppression
of cyclin D2 expression has also been shown to decrease the
proliferation of neural stem cells (Garthe et al., 2014; Kerever
et al., 2014). MFG-E8 has been shown to positively regulate cyclin
D2 expression in neural stem cells (Cheyuo et al., 2015). The
upstream pathway involving MFG-E8’s receptor, αv β3 -integrin,
might activate unknown downstream molecules which govern
cyclin D2 expression in neural stem cells (Cheyuo et al., 2015).
MFG-E8 has been shown to activate PI3K/Akt pathway (Zhao
et al., 2017; Gao et al., 2018). Moreover, recent studies have
also revealed the MFG-E8-mediated upregulation of mammalian
target of rapamycin (mTOR; Khalifeh-Soltani et al., 2014; Gao
et al., 2018). Cyclin D2 is one of the target genes of mTOR
(Balcazar et al., 2009). Therefore, MFG-E8 signaling via αv β3 integrin could potentially activate the PI3K/Akt/mTOR pathway
leading to upregulation of cyclin D2 expression and asymmetrical
division in NSPC. The potential induction of asymmetrical
division of NSPC by MFG-E8-induced upregulation of cyclin
D2, could also drive both proliferation and quiescence of NSPC,
deducing from the finding by Bast et al. (2018) that asymmetrical
division is the main driver of NSPC quiescence. Beside MFG-E8mediated αv β3 integrin signal transduction in NSPC, Zhou et al.
(2018) recently described a role for MFG-E8 signaling via α8 β1 integrin signaling. The β1 -integrin subunit is the predominant
integrin expressed in NSPC (Flanagan et al., 2006). The α8 integrin subunit and its association with β1 -subunit was first
described in neurons and to some extend in epithelial cells, in
chick embryos (Bossy et al., 1991). MFG-E8 signaling through
this receptor was reported to promote RGL quiescence through
downregulation of mTOR1 (Zhou et al., 2018). A proposed model
demonstrating the findings of these recent studies on the novel
role of MFG-E8 in neurogenesis has been presented in Figure 1.

FIGURE 1 | Schematic representation of proposed MFG-E8 signaling in radial
glial cells (RGL) via αv β3 /PI3K/Akt/mTOR pathway. (A) MFG-E8 binds to
αv β3 -integrin on the basal process of RGL, leading to activation of PI3K. PI3K
phosphorylates PIP2 and produces PIP3. PIP3 then activates PDK1 which
subsequently activates Akt by phosphorylation. Phosphorylation of Akt
activates mTOR. mTOR activates several transcription factors leading to the
downstream activation of several target genes, including CCDN2, which
produces cyclin D2 mRNA. Cyclin D2 mRNA is transported to the basal
process by a carrier protein that recognizes its cis-transport element that
resides in the 30 UTR region. The mRNA is then translated in the basal
process by ribosomes into cyclin D2 protein. Asymmetric division of RGL
leads to the production of two daughter cells. (B) Intermediate progenitor, with
no cyclin D2, which subsequently undergoes differentiation into a neuron, and
(C) apical progenitor, which has inherited the cyclin D2. This apical progenitor
has the capacity for self-renewal through further asymmetric divisions. On the
other hand, depending on additional signals received, this RGL may go into
quiescence. MFG-E8, milk fact globule-epidermal growth factor-factor VIII;
RGL, radial glial cells; PIP2, phosphatidylinositol 3,4-bisphosphate; PIP3,
phosphatidylinositol 3,4,5-trisphosphate; PDK1,
3-phosphoinositide-dependent kinase 1; mTOR, mammalian target of
rapamycin.

MFG-E8-MEDIATED ANGIOGENESIS
MFG-E8 is a multi-functional glycoprotein known to mediate
other cellular functions other than its typical role in phagocytosis
and anti-inflammation (Aziz et al., 2011; Li et al., 2013). MFGE8 has been shown to promote post-ischemic neovascularization
via αv β3 - and αv β5 -dependent Akt phosphorylation and vascular
endothelial growth factor (VEGF) induction in endothelial cells
(Silvestre et al., 2005). MFG-E8 has also been shown to promote
wound healing by stimulating vascular capillary formation
(Uchiyama et al., 2014). Uchiyama et al. (2014) found that in
the dermis of normal murine and human skin, accumulations
of MFG-E8 were found around CD31 expressing blood vessels,
and MFG-E8 co-localized with PDGFRβ(+), αSMA(+), and
NG2(+) pericytes. They found that MFG-E8 increased capillary
formation and myofibroblast recruitment, leading to increased
wound healing (Uchiyama et al., 2014). Planar capillaries are
an integral part of the neural stem cell niche, as described
above (Tavazoie et al., 2008). The endothelial cells secrete trophic
factors that support NSPC proliferation and differentiation. In

Frontiers in Neuroscience | www.frontiersin.org

addition, it has also been shown that direct cell to cell interaction
between NSPC and endothelial cells promote quiescence through
ephrinB2 and Jagged1 signal-transduction pathways (Ottone
et al., 2014). Age-related microvascular disease has been shown
to contribute to decline in neurogenesis and dementia (Apple and
Kokovay, 2017). Thus, in addition to modulating NSPC activity,
MFG-E8 may also contribute to maintaining the neural stem cell
niche by promoting angiogenesis.

MFG-E8 DELIVERY INTO THE BRAIN
Even though the BBB at the neural stem cell niche is leaky,
as described above (Tavazoie et al., 2008), it is not clear
whether intravenously administered MFG-E8 can reach the
neural stem cell niche. Indeed, Falborg et al. (2010) assessed
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Exosomes are 30–100 nm vesicles formed within endosomes
in cells and released into the extracellular space (CondeVancells et al., 2008; Colombo et al., 2014; Vogel et al.,
2018). Exosomes contain a variety of molecules such as
microRNAs, cell membrane proteins and adhesion molecules,
which allow them to modulate cellular activity (Conde-Vancells
et al., 2008). The membranes of exosomes contain lipids such
as phosphatidylserine, sphingomyelin, and phosphatidylcholine
(Subra et al., 2007). Exosomes have the advantage of being
able to cross the BBB (Qu et al., 2018; Tian et al., 2018).
Other advantages of exosomes as a therapeutic delivery tools
include the fact that isolated exosomes can be engineered by
loading them with the desired therapeutic agent (Qu et al., 2018).
Moreover, exosomes can be delivered non-invasively via the
intranasal route (Long et al., 2017). The binding of MFG-E8 to
phosphatidylserine allows MFG-E8 to be isolated with exosomes.
MFG-E8-enriched exosomes from dendritic cells have previously
been isolated and used for the treatment of experimental sepsis
(Miksa et al., 2009). Because of the universal presence of
phosphatidylserine in all cell membranes, even exosomes isolated
from cells which do not express MFG-E8 can also be engineered
by loading them with MFG-E8 through its binding to the
phosphatidylserine. Exosomal MFG-E8 delivery across the BBB
has not been studied. However, given the fact that exosomes
can effectively cross the BBB, we would expect that MFG-E8
can be delivered to the brain via exosomal transport. Thus, we
propose that exosomal MFG-E8, administered non-invasively

the biodistribution of intravenously administered radio-labeled
MFG-E8 (99m Tc-HYNIC-lactadherin) and found that there
was no uptake in the brain. In a recent study of the effect of
MFG-E8 on neurogenesis, the BBB was bypassed by delivering
MFG-E8 to the brain via intracerebroventricular administration
(Cheyuo et al., 2015). Intracerebroventricular administration of
drugs is an invasive route of drug delivery which would not be
suitable for long-term treatment of chronic neurodegenerative
diseases. Neurogenesis involves the proliferation of NSPC in
the neural stem cell niche, where the BBB is leaky, followed by
the migration of NSPC out of the niche to distant parts of the
brain, with intact BBB, for differentiation. Thus, the development
of an effective therapeutic strategy for stimulating neurogenesis
in neurodegenerative diseases will require the non-invasive or
minimally invasive delivery of an agent that can reach both the
neural stem cell niche via the leaky BBB and also be able to
cross the intact BBB to influence migration and differentiation
of NSPC. The pharmacokinetics of intravenously administered
lactadherin (MFG-E8) was studied by Poulsen et al. (2013) in
pigs. Even though the effective half-life of MFG-E8 was not
determined, they found that a large percentage of intravenously
administered MFG-E8 was rapidly sequestered in the liver
(Poulsen et al., 2013). Thus, intravenous administration of MFGE8 for the long-term treatment of chronic neurodegenerative
disease would require daily multiple injections, which would
be associated with significant patient discomfort and therefore
increased non-compliance.

FIGURE 2 | Proposed strategies for effective delivery of MFG-E8 to neural stem/progenitor cells (NSPCs) in the brain. The blood–brain barrier (BBB) is made up of
endothelial tight junctions and astrocyte endfeet. We propose that MFG-E8-enriched exosomes, administered either intranasally or intravenously, can effectively
cross the BBB and deliver MFG-E8 to NSPC in the brain. MSP68 is a small peptide derivative of MFG-E8, which we presume would be able to cross the BBB due to
its small size. Lastly, MFG-E8 can also be over-expressed in NSPC by plasmid-mediated delivery of the MFG-E8 gene into NSPC. Both MFG-E8 and MSP68 signal
through the αv β3 integrin receptor.
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In addition, further research is needed in establishing strategies
for effective delivery of MFG-E8 across the BBB for therapeutic
purposes. In this regard, the study of the pharmacokinetics
and pharmacodynamics of exosomal preparations of MFG-E8
holds great promise. Currently, only in vitro and small animal
in vivo studies of MFG-E8 effect on neurogenesis have been
performed. To accelerate the therapeutic development of MFGE8 for neurodegenerative diseases, we propose the investigation
of the effects of MFG-E8 on neurogenesis in larger gyrencephalic
animals, whose embryonic corticogenesis and adult neuroarchitecture are similar to humans (Sun and Hevner, 2014).
Other avenues for harnessing the therapeutic effects of MFGE8 could be pharmacological upregulation, using agents such as
prolactin (Aziz et al., 2008, 2011). In conclusion, the tremendous
therapeutic potential of MFG-E8 for neurodegenerative diseases
requires further preclinical development.

via the intranasal route or intravenously, could be a long-term
delivery strategy for stimulating neurogenesis for therapeutic
purposes in neurodegenerative diseases.
Other therapeutic strategies may include, use of small peptide
derivative of MFG-E8, MSP68 (VRGDV), which may have a
higher probability of crossing the BBB due to its small size (Yang
et al., 2015; Hirano et al., 2017). However, the effect of MSP68 on
neural stem cells remains to be investigated. Additional strategies
for harnessing the therapeutic potential of MFG-E8 for chronic
neurodegenerative may include the development of gene therapy
whereby the MFG-E8 gene expression is increased in the neural
stem cell niche using recombinant viral technology. The potential
strategies for effective delivery of MFG-E8 to NSPC in the brain
are summarized in Figure 2.

FUTURE PERSPECTIVES AND
CONCLUSION
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